Reduction in pain intensity · acute soft tissue injury
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve clinical remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to maintain clinical response · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to maintain clinical response (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with quiescent ulcerative colitis
Tofacitinib leads to lower failure to achieve endoscopic remission (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in adverse events (5 mg/10 mg) compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Change in serum albumin · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Mid‐arm muscle circumference · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Lean mass · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Quality of life · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Cost · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
CRP · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
IL‐6 · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Serum potassium · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Serum phosphate · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Serum albumin (end of intervention) · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Serum prealbumin · people with CKD requiring dialysis
1 finding from 1 review
Intervention not reported
Death · people with CKD requiring dialysis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Intolerance to therapy ‐ Gastrointestinal intolerance · people with CKD requiring dialysis
The intervention showed no clear difference in intolerance to therapy ‐ Gastrointestinal intolerance (low certainty).
1 finding from 1 review